Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colitis, Ulcerative clinical trials
10 of 29 indexed Colitis, Ulcerative trials are currently recruiting.
29 US clinical trials · 10 currently recruiting
Colitis, Ulcerative is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 10 of these trials.
The research picture
Colitis, Ulcerative has 29 registered US clinical trials, 10 of them open to new participants right now, about 34% of the total.
- 10
- recruiting participants now
- 34%
- of trials open to enrollment
- 12
- in Phase 3–4 (later-stage)
- 10
- top sponsor: Janssen Research & Development
Active & Recent Trials
29 total, page 1 of 1
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Merck Sharp & Dohme
NCT06651281
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Janssen Scientific Affairs
NCT04372108
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT07196748
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Spyre Therapeutics
NCT07012395
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Pfizer
NCT06398626
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Sanofi
NCT06867094
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development
NCT06663332
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Bristol-Myers Squibb
NCT05076175
Therapeutic Endpoint in Pediatric IBD Conditions
Children's National Research Institute
NCT06065228
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
University of California, San Diego
NCT04721873
Determination of the Optimal Treatment Target in Ulcerative Colitis
Alimentiv
NCT04259138
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT05242484
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT05528510
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
NCT05611671
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Teva Branded Pharmaceutical Products R&D
NCT05668013
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Oppilan Pharma
NCT05156125
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Sanofi
NCT05588843
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Janssen Research & Development
NCT05092269
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT06260163
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT03596645
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Sanofi
NCT05731128
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT00487539
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT02407236
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Takeda
NCT02497469
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Teva Branded Pharmaceutical Products R&D
NCT05499130
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Takeda
NCT03029143
Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.
Telavant
NCT02840721
A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
Janssen Research & Development
NCT01900574
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
Takeda
NCT02559713
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 13 |
| Phase 3 | 9 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Colitis, Ulcerative Trial Landscape
29 indexed Colitis, Ulcerative studies · 10 recruiting (34%).
Phase mix: 12 late (III/IV) vs 14 early (I/II).
Top sponsor: Janssen Research & Development (10 trials), 9 others listed. 29 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Colitis, Ulcerative?
PlainTrial tracks 29 US clinical trials for Colitis, Ulcerative, of which 10 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Colitis, Ulcerative?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.